Psychedelics and mental health: a population study
Open accessAbstract
BACKGROUND: The classical serotonergic psychedelics LSD, psilocybin, mescaline are not known to cause brain damage and are regarded as non-addictive. Clinical studies do not suggest that psychedelics cause long-term mental health problems. Psychedelics have been used in the Americas for thousands of years. Over 30 million people currently living in the US have used LSD, psilocybin, or mescaline. OBJECTIVE: To evaluate the association between the lifetime use of psychedelics and current mental health in the adult population. METHOD: Data drawn from years 2001 to 2004 of the National Survey on Drug Use and Health consisted of 130,152 respondents, randomly selected to be representative of the adult population in the United States. Standardized screening measures for past year mental health included serious psychological distress (K6 scale), mental health treatment (inpatient, outpatient, medication, needed but did not receive), symptoms of eight psychiatric disorders (panic disorder, major depressive episode, mania, social phobia, general anxiety disorder, agoraphobia, posttraumatic stress disorder, and non-affective psychosis), and seven specific symptoms of non-affective psychosis. We calculated weighted odds ratios by multivariate logistic regression controlling for a range of sociodemographic variables, use of illicit drugs, risk taking behavior, and exposure to traumatic events. RESULTS: 21,967 respondents (13.4% weighted) reported lifetime psychedelic use. There were no significant associations between lifetime use of any psychedelics, lifetime use of specific psychedelics (LSD, psilocybin, mescaline, peyote), or past year use of LSD and increased rate of any of the mental health outcomes. Rather, in several cases psychedelic use was associated with lower rate of mental health problems. CONCLUSION: We did not find use of psychedelics to be an independent risk factor for mental health problems.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Both mindfulness-based interventions and psychedelic-assisted therapy have successfully demonstrated reductions in clinical symptomatology in healthy individuals.
“Both interventions have also successfully demonstrated reductions in clinical symptomatology in healthy individuals (65, 66).”
From Examining the Potential Synergistic Effects Between Mindfulness Training and Psychedelic-Assisted Therapy (2021) · cites this paper as [65]
The Results (Logistic Regression Results; page not provided) report lower rates of a few psychiatric symptoms among people with lifetime use of specific psychedelics. But this was an association, not a demonstrated reduction following psychedelic-assisted therapy. The Discussion (Clinical Studies in Healthy Volunteers; page not provided) reports an absence of lasting adverse effects, not symptom reductions, and the paper does not assess mindfulness-based interventions. (LLM, conf=0.83)
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Screening for serious mental illness in the general population
Kessler, R. C., Barker, P. R., Colpe, L. J., Epstein, J. F., Gfroerer, J. C., Hiripi, E., Howes, M. J., Normand, S.-L. T., Manderscheid, R. W., Walters, E. E., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.2.184 · Cited by 5,692 · see citing works
Relaxing the Rule of Ten Events per Variable in Logistic and Cox Regression
Vittinghoff, E., & McCulloch, C. E. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwk052 · Cited by 4,359 · see citing works
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681 · see citing works
Lifetime Prevalence of Psychotic and Bipolar I Disorders in a General Population
Perälä, J., Suvisaari, J., Saarni, S. I., Kuoppasalmi, K. I., Isometsä, E. T., Pirkola, S. P., Partonen, T., Tuulio‐Henriksson, A., Hintikka, J., Kieseppä, T., et al. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.1.19 · Cited by 1,523 · see citing works
Development of a rational scale to assess the harm of drugs of potential misuse
Nutt, D., King, L. A., Saulsbury, W., & Blakemore, C. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60464-4 · Cited by 1,302 · cited 1× · see citing works
“LSD and psilocybin are consistently ranked in expert assessments as causing less harm to both individual users and society than alcohol, tobacco, and most other common recreational drugs [16–19].”
BackgroundEuropean Monitoring Centre for Drugs and Drug Addiction
Anderson, M. (2014) · European Union regulations | European Encyclopedia of law · Cited by 1,214 · see citing works
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · see citing works
Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects
Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2358-5 · Cited by 932 · see citing works
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · see citing works
Griffiths, R., Richards, W., Johnson, M., McCann, U., & Jesse, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108094300 · Cited by 905 · see citing works
Drugs in Pregnancy and Lactation. A Reference Guide to Fetal and Neonatal Risk.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-99-1-144_6 · Cited by 851 · see citing works
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 3× · see citing works
“Controlled studies have not suggested that use of psychedelics lead to long-term mental health problems [8,9,13,20].”
BackgroundEquity, social determinants and public health programmes
Blas, E., & Kurup, A. S. (2010) · University Libraries (University of Maryland) · doi:10.13016/nvnm-a5xt · Cited by 457 · see citing works
Drugs of abuse and the elicitation of human aggressive behavior
Hoaken, P. N. S., & Stewart, S. H. (2003) · Addictive Behaviors · doi:10.1016/j.addbeh.2003.08.033 · Cited by 405 · see citing works
Prevalence of hallucinations and their pathological associations in the general population
Ohayon, M. M. (2000) · Psychiatry Research · doi:10.1016/s0165-1781(00)00227-4 · Cited by 372 · see citing works
Bouso, J. C., González, D., Fondevila, S., Cutchet, M., Fernández, X., Ribeiro Barbosa, P. C., Alcázar-Córcoles, M. Á., Araújo, W. S., Barbanoj, M. J., Fábregas, J. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042421 · Cited by 313 · see citing works
Hallucinogen persisting perception disorder: what do we know after 50 years?
Halpern, J. H. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(02)00306-x · Cited by 219 · see citing works
Harm potential of magic mushroom use: A review
van Amsterdam, J., Opperhuizen, A., & van den Brink, W. (2011) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2011.01.006 · Cited by 209 · see citing works
Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
van Amsterdam, J., Opperhuizen, A., Koeter, M., & van den Brink, W. (2010) · European Addiction Research · doi:10.1159/000317249 · Cited by 191 · see citing works
Psychological and Cognitive Effects of Long-Term Peyote Use Among Native Americans
Halpern, J. H., Sherwood, A. R., Hudson, J. I., Yurgelun-Todd, D. A., & Pope, H. G. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.038 · Cited by 187 · see citing works
Visual Phenomenology of the LSD Flashback
Abraham, H. D. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070074009 · Cited by 170 · see citing works
Kuijpers, H. J. H., van der Heijden, F. M. M. A., Tuinier, S., & Verhoeven, W. M. A. (2007) · Psychopathology · doi:10.1159/000108125 · Cited by 164 · see citing works
PAHNKE'S "GOOD FRIDAY EXPERIMENT' A LONG-TERM FOLLOW-UP AND METHODOLOGICAL CRITIQUE
Doblin, R. (1991) · Cited by 163 · see citing works
(1992) · PubMed · Cited by 157 · see citing works
LSD Psychosis or LSD-Induced Schizophrenia?
Vardy, M. M. (1983) · Archives of General Psychiatry · doi:10.1001/archpsyc.1983.01790070067008 · Cited by 144 · see citing works
Mental disorders: equity and social determinants.
Patel, V., Lund, C., Hatherill, S., Plagerson, S., Corrigall, J., Funk, M., Flisher, A. J., Blas, E., & Kurup, A. S. (2010) · Cited by 132 · see citing works
Over 30 million psychedelic users in the United States
Krebs, T. S., & Johansen, P.-Ø. (2013) · F1000Research · doi:10.12688/f1000research.2-98.v1 · Cited by 124 · see citing works
Self-citationMcGlothlin, W. H. (1971) · Archives of General Psychiatry · doi:10.1001/archpsyc.1971.01750070037005 · Cited by 117 · see citing works
Carhart-Harris, R. L., & Nutt, D. (2010) · Journal of Substance Use · doi:10.3109/14659890903271624 · Cited by 106 · see citing works
Bruhn, J. G., Smet, P. A. G. M. D., El-Seedi, H. R., & Beck, O. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08701-9 · Cited by 104 · see citing works
The Recanting of Earlier Reported Drug Use by Young Adults
Johnston, L. D., & O’Malley, P. M. (1997) · PsycEXTRA Dataset · doi:10.1037/e495622006-005 · Cited by 93 · see citing works
Voigt, K., Wollburg, E., Weinmann, N., Herzog, A., Meyer, B., Langs, G., & Löwe, B. (2012) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2012.08.020 · Cited by 86 · see citing works
Harms associated with psychoactive substances: findings of the UK National Drug Survey
Morgan, C. J. A., Muetzelfeldt, L., Muetzelfeldt, M., Nutt, D., & Curran, H. V. (2009) · Journal of Psychopharmacology · doi:10.1177/0269881109106915 · Cited by 80 · see citing works
Navajo Peyote Use: Its Apparent Safety
Bergman, R. (1971) · American Journal of Psychiatry · doi:10.1176/ajp.128.6.695 · Cited by 71 · see citing works
Stigma of mental illness in Japan
Desapriya, E., & Iwase, N. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08698-1 · Cited by 70 · see citing works
Bar-El, Y., Durst, R., Katz, G., Zislin, J., Strauss, Z., & Knobler, H. Y. (2000) · British Journal of Psychiatry · doi:10.1192/bjp.176.1.86 · Cited by 65 · see citing works
Marona‐Lewicka, D., & Nichols, D. E. (2007) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2007.06.001 · Cited by 64 · see citing works
Hallock, R. M., Dean, A. C., Knecht, Z. A., Spencer, J., & Taverna, E. C. (2012) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2012.11.010 · Cited by 52 · see citing works
Prevalence and correlates of anomalous experiences in a large non‐clinical sample
Pechey, R., & Halligan, P. W. (2011) · Psychology and Psychotherapy Theory Research and Practice · doi:10.1111/j.2044-8341.2011.02024.x · Cited by 48 · see citing works
The Peyote Religion among the Navaho
Roscoe, W., & Aberle, D. F. (1993) · The American Indian Quarterly · doi:10.2307/1184808 · Cited by 46 · see citing works
Occurrence and use of hallucinogenic mushrooms containing psilocybin alkaloids
Andersson, C., Gry, J., & Kristinsson, J. (2009) · TemaNord · doi:10.6027/tn2008-606 · Cited by 41 · see citing works
Taylor, M., Mackay, K., Murphy, J., McIntosh, A. M., McIntosh, C., Anderson, S. M., & Welch, K. A. (2012) · BMJ Open · doi:10.1136/bmjopen-2011-000774 · Cited by 35 · see citing works
Apparitional Experiences of New Faces and Dissociation of Self-Identity during Mirror Gazing
Caputo, G. (2010) · Perceptual and Motor Skills · doi:10.2466/pms.110.c.1125-1138 · Cited by 32 · see citing works
Long-term psychological effects of LSD.
McWilliams, S. A., & Tuttle, R. J. (1973) · Psychological Bulletin · doi:10.1037/h0034411 · Cited by 27 · see citing works
Kuzenko, N., Sareen, J., Beesdo‐Baum, K., Perkonigg, A., Höfler, M., Simm, J., Lieb, R., & Wïttchen, H. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2010.01633.x · Cited by 26 · see citing works
LSD: still with us after all these years
(1995) · Choice Reviews Online · doi:10.5860/choice.32-4536 · Cited by 21 · see citing works
HALLUCINOGENIC DRUGS: A PERSPECTIVE WITH SPECIAL REFERENCE TO PEYOTE AND CANNABIS,
McGlothlin, W. H. (1964) · Defense Technical Information Center (DTIC) · Cited by 18 · see citing works
Bonn‐Miller, M. O., Bernstein, A., Sachs‐Ericsson, N., Schmidt, N. B., & Zvolensky, M. J. (2006) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2006.09.014 · Cited by 17 · see citing works
Sunderland, M., Andrews, G., Slade, T. N., & Peters, L. (2010) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-010-0247-6 · Cited by 16 · see citing works
APPARITIONAL EXPERIENCES OF NEW FACES AND DISSOCIATION OF SELF-IDENTITY DURING MIRROR GAZING1
Caputo, G. (2010) · Perceptual and Motor Skills · doi:10.2466/pms.110.3c.1125-1138 · Cited by 16 · see citing works
Comments on Jerusalem syndrome
Kalian, M., & Witztum, E. (2000) · The British Journal of Psychiatry · doi:10.1192/bjp.176.5.492-a · Cited by 15 · see citing works
Psychotomimetic effects of PCP, LSD, and Ecstasy: pharmacological models of schizophrenia?
Catts, V. S., & Catts, S. V. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511789977.011 · Cited by 12 · see citing works
LSD Use and Flashbacks in Alcoholic Patients
Batzer, W. B., Ditzler, T. F., & Brown, C. R. (1999) · Journal of Addictive Diseases · doi:10.1300/j069v18n02_06 · Cited by 12 · see citing works
Field-testing the criteria for "visual snow" (positive persistent visual disturbance)
Schankin, C. J., Maniyar, F., & Goadsby, P. J. (2012) · F1000Research · doi:10.7490/f1000research.1090714.1 · Cited by 11 · see citing works
Stendhal syndrome: a case of cultural overload: Figure 1
Nicholson, T. R., Pariante, C. M., & McLoughlin, D. M. (2009) · BMJ Case Reports · doi:10.1136/bcr.06.2008.0317 · Cited by 10 · see citing works
Soviet-style psychiatry is alive and well in the People's Republic
Lyons, D. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.178.4.380-b · Cited by 6 · see citing works
Who is politicising psychiatry in China?
Lee, S. (2001) · The British Journal of Psychiatry · doi:10.1192/bjp.179.2.178-a · Cited by 6 · see citing works
The Thaw: Reclaiming the Person for Psychiatry
Genova, P. (2002) · Cited by 2 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [36]Laing R, Siegel JA, editors (2003) Hallucinogens: A Forensic Drug Handbook. Academic Press.
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., Mennenga, S. E., Belser, A., Kalliontzi, K., Babb, J., et al. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675512 · Cited by 1,698 · see citing works
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · see citing works
REBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180 · see citing works
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · see citing works
Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI).
Nour, M. M., Evans, L., Nutt, D., & Carhart-Harris, R. L. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00269 · Cited by 470 · see citing works
Predicting responses to psychedelics: a prospective study
Haijen, E. C. H. M., Kaelen, M., Roseman, L., Timmermann, C., Kettner, H., Russ, S., Nutt, D., Daws, R. E., Hampshire, A. D. G., Lorenz, R., et al. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00897 · Cited by 417 · see citing works
Hendricks, P. S., Thorne, C. B., Clark, C. B., Coombs, D., & Johnson, M. W. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565653 · Cited by 360 · see citing works
Psychiatry & the psychedelic drugs. Past, present & future
Rucker, J. J. H., Iliff, J., & Nutt, D. J. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.040 · Cited by 343 · see citing works
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science
Schlag, A. K., Aday, J. S., Salam, I., Neill, J. C., & Nutt, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069100 · Cited by 327 · see citing works
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., Riba, J., Zuardi, A. W., & Hallak, J. E. C. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316638008 · Cited by 306 · see citing works
The paradoxical psychological effects of lysergic acid diethylamide LSD
Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., Feilding, A., & Nutt, D. J. (2016) · Psychological Medicine · doi:10.1017/s0033291715002901 · Cited by 293 · see citing works
Psychedelics not linked to mental health problems or suicidal behavior: A population study
Johansen, P.-Ø., & Krebs, T. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568039 · Cited by 268 · see citing works
Self-citationClassical psychedelics for the treatment of depression and anxiety: A systematic review
Muttoni, S., Ardissino, M., & John, C. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.07.076 · Cited by 256 · see citing works
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development
Schenberg, E. E. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00733 · Cited by 251 · see citing works
Psychedelics in Psychiatry: Neuroplastic, Immunomodulatory, and Neurotransmitter Mechanisms
Inserra, A., De Gregorio, D., & Gobbi, G. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000056 · Cited by 232 · see citing works
George, J. R., Michaels, T. I., Sevelius, J. M., & Williams, M. T. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.015 · Cited by 230 · see citing works
Psychedelics, personality and political perspectives.
Nour, M. M., Evans, L., & Carhart-Harris, R. L. (2017) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2017.1312643 · Cited by 226 · see citing works
Extended difficulties following the use of psychedelic drugs: A mixed methods study
Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R. G., Luke, D. P., Michelle, K., & Prideaux, E. (2023) · PLoS ONE · doi:10.1371/journal.pone.0293349 · Cited by 207 · see citing works
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · see citing works
Unifying Theories of Psychedelic Drug Effects
Swanson, L. R. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00172 · Cited by 181 · see citing works
Lyons, T., & Carhart-Harris, R. L. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881117748902 · Cited by 183 · see citing works
Neuroimaging the consciousness of self: Review, and conceptual-methodological framework
Frewen, P., Schroeter, M. L., Riva, G., Cipresso, P., Fairfield, B., Padulo, C., Kemp, A. H., Palaniyappan, L. K., Owolabi, M. O., Kusi‐Mensah, K., et al. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.01.023 · Cited by 177 · see citing works
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177 · see citing works
Microdosing psychedelics: personality, mental health, and creativity differences in microdosers
Anderson, T., Petranker, R., Rosenbaum, D., Weissman, C. R., Dinh-Williams, L.-A., Hui, K., Hapke, E., & Farb, N. A. S. (2019) · Psychopharmacology · doi:10.1007/s00213-018-5106-2 · Cited by 174 · see citing works
Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies
SANTOS, R. G. D., Bouso, J. C., & Hallak, J. E. C. (2017) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316689030 · Cited by 168 · see citing works
Legal highs: staying on top of the flood of novel psychoactive substances
Baumeister, D., Tojo, L. M., & Tracy, D. K. (2015) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314559539 · Cited by 160 · see citing works
Powerful substances in tiny amounts: An interview study of psychedelic microdosing
Johnstad, P. G. (2018) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072517753339 · Cited by 155 · see citing works
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148 · see citing works
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 146 · see citing works
Ethics and ego dissolution: the case of psilocybin
Smith, W. R., & Sisti, D. (2021) · Journal of Medical Ethics · doi:10.1136/medethics-2020-106070 · Cited by 146 · see citing works
Celidwen, Y., Redvers, N., Githaiga, C., Calambás, J., Bedriñana, K. G. A., Chindoy, M. E., Vitale, R., Rojas, J. N., Mondragón, D., Rosalío, Y. V., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100410 · Cited by 144 · see citing works
DARK Classics in Chemical Neuroscience: Psilocybin
Geiger, H. A., Wurst, M. G., & Daniels, R. N. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00186 · Cited by 142 · see citing works
Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118769063 · Cited by 140 · see citing works
Galvão-Coelho, N. L., Marx, W., Gonzalez, M., Sinclair, J., de Manincor, M., Perkins, D., & Sarris, J. (2021) · Psychopharmacology · doi:10.1007/s00213-020-05719-1 · Cited by 137 · see citing works
Serotonergic psychedelics and personality: A systematic review of contemporary research
Bouso, J. C., dos Santos, R. G., Alcázar-Córcoles, M. Á., & Hallak, J. E. C. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.004 · Cited by 134 · see citing works
Shalit, N., Rehm, J. T., & Lev‐Ran, S. (2018) · Addictive Behaviors · doi:10.1016/j.addbeh.2018.09.020 · Cited by 129 · see citing works
Reiche, S., Hermle, L., Gutwinski, S., Jungaberle, H., Gasser, P., & Majić, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.012 · Cited by 122 · see citing works
Classical hallucinogens as antidepressants? A review of pharmacodynamics and putative clinical roles
Baumeister, D., Barnes, G. L., Giaroli, G., & Tracy, D. K. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314527985 · Cited by 121 · see citing works
Morisano, D., Babor, T. F., & Robaina, K. (2014) · Nordic Studies on Alcohol and Drugs · doi:10.2478/nsad-2014-0002 · Cited by 119 · see citing works
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117 · see citing works
Dark Classics in Chemical Neuroscience:N,N-Dimethyltryptamine (DMT)
Cameron, L. P., & Olson, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00101 · Cited by 117 · see citing works
A Survey of American Psychiatrists' Attitudes Toward Classic Hallucinogens
Barnett, B. S., Siu, W. O., & Pope, H. G. (2018) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000828 · Cited by 116 · see citing works
Case analysis of long-term negative psychological responses to psychedelics
Bremler, R., Katati, N., Shergill, P., Erritzøe, D., & Carhart-Harris, R. L. (2023) · Scientific Reports · doi:10.1038/s41598-023-41145-x · Cited by 121 · see citing works
Classical hallucinogens and neuroimaging: A systematic review of human studies
dos Santos, R. G., Osório, F. L., Crippa, J. A. S., & Hallak, J. E. C. (2016) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.10.026 · Cited by 107 · see citing works
Does Psychedelic Therapy Have a Transdiagnostic Action and Prophylactic Potential?
Kočárová, R., Horáček, J., & Carhart-Harris, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.661233 · Cited by 96 · see citing works
Hendricks, P. S., Crawford, M. S., Cropsey, K. L., Copes, H., Sweat, N. W., Walsh, Z., & Pavela, G. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117735685 · Cited by 93 · see citing works
The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant
Sessa, B. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4713-7 · Cited by 92 · see citing works
Gregorio, D. D., Enns, J. P., Núñez, N. A., Posa, L., & Gobbi, G. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.07.008 · Cited by 92 · see citing works
Livne, O., Shmulewitz, D., Walsh, C. A., & Hasin, D. S. (2022) · Addiction · doi:10.1111/add.15987 · Cited by 92 · see citing works
Dark Classics in Chemical Neuroscience: Lysergic Acid Diethylamide (LSD)
Nichols, D. E. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.8b00043 · Cited by 91 · see citing works
Nichols, D. E., & Grob, C. S. (2018) · Forensic Science International · doi:10.1016/j.forsciint.2018.01.006 · Cited by 89 · see citing works
Psychedelics and health behaviour change
Teixeira, P. J., Johnson, M. W., Timmermann, C., Watts, R., Erritzøe, D., Douglass, H. M., Kettner, H., & Carhart-Harris, R. L. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211008554 · Cited by 96 · see citing works
Leptourgos, P., Fortier, M., Carhart-Harris, R. L., Corlett, P. R., Dupuis, D., Halberstadt, A. L., Kometer, M., Kozáková, E., Larøi, F., Noorani, T. N., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa117 · Cited by 87 · see citing works
Therapeutic Applications of Classic Hallucinogens
Bogenschutz, M. P., & Ross, S. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_464 · Cited by 85 · see citing works
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84 · see citing works
Self-reported negative outcomes of psilocybin users: A quantitative textual analysis
Bienemann, B., Ruschel, N. S., Campos, M. L. P., Negreiros, M., & Mograbi, D. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229067 · Cited by 61 · see citing works
More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression
Lyons, T., & Carhart-Harris, R. L. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01721 · Cited by 77 · see citing works
Morton, E., Sakai, K., Ashtari, A., Pleet, M., Michalak, E. E., & Woolley, J. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221131997 · Cited by 78 · see citing works
Ona, G., Kohek, M., Massaguer, T., Gomariz, A., Jiménez, D. F., Dos Santos, R. G., Hallak, J. E. C., Alcázar-Córcoles, M. Á., & Bouso, J. C. (2019) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2019.1567961 · Cited by 76 · see citing works
Associations between lifetime classic psychedelic use and markers of physical health
Simonsson, O., Sexton, J. D., & Hendricks, P. S. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881121996863 · Cited by 74 · see citing works
Psilocybin in neuropsychiatry: a review of its pharmacology, safety, and efficacy
Dodd, S., Norman, T. R., Eyre, H. A., Stahl, S. M., Phillips, A., Carvalho, A. F., & Berk, M. (2023) · CNS Spectrums · doi:10.1017/s1092852922000888 · Cited by 73 · see citing works
Tulver, K., Kaup, K., Laukkonen, R., & Aru, J. (2023) · Consciousness and Cognition · doi:10.1016/j.concog.2023.103494 · Cited by 72 · see citing works
Psychedelics as a novel approach to treating autoimmune conditions
Thompson, C., & Szabó, A. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.10.001 · Cited by 71 · see citing works
Positive psychology in the investigation of psychedelics and entactogens: a critical review
Jungaberle, H., Thal, S., Zeuch, A., Rougemont-Bücking, A., von Heyden, M., Aicher, H., & Scheidegger, M. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.034 · Cited by 70 · see citing works
Psychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69 · see citing works
Uthaug, M. V., Davis, A. K., Haas, T. F., Davis, D. D., Dolan, S. B., Lancelotta, R., Timmermann, C., & Ramaekers, J. G. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013583 · Cited by 65 · see citing works
Use of psilocybin (“mushrooms”) among US adults: 2015–2018
Yockey, R. A., & King, K. A. (2021) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00159 · Cited by 64 · see citing works
Self-transcendent experience: a grounded theory study
Garcia-Romeu, A., Himelstein, S., & Kaminker, J. (2015) · Qualitative Research · doi:10.1177/1468794114550679 · Cited by 42 · see citing works
Jones, G. M., & Nock, M. K. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211058923 · Cited by 62 · see citing works
Neitzke‐Spruill, L. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.022 · Cited by 61 · see citing works
Argento, E., Strathdee, S. A., Tupper, K. W., Braschel, M. C., Wood, E., & Shannon, K. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016025 · Cited by 62 · see citing works
SANTOS, R. G. D., Bouso, J. C., Rocha, J. M., Rossi, G. N., & Hallak, J. E. C. (2021) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s300656 · Cited by 60 · see citing works
Two Models of Legalization of Psychedelic Substances
Smith, W., & Appelbaum, P. S. (2021) · JAMA · doi:10.1001/jama.2021.12481 · Cited by 59 · see citing works
Pattern breaking: a complex systems approach to psychedelic medicine
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2023) · Neuroscience of Consciousness · doi:10.1093/nc/niad017 · Cited by 66 · see citing works
Elsey, J. W. B. (2017) · Drug Science Policy and Law · doi:10.1177/2050324517723232 · Cited by 57 · see citing works
Psilocybin for Trauma-Related Disorders
Khan, A. J., Bradley, E., O’Donovan, A., & Woolley, J. (2022) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2022_366 · Cited by 55 · see citing works
Sabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 53 · see citing works
Whelan, A., & Johnson, M. I. (2018) · Pain Management · doi:10.2217/pmt-2017-0068 · Cited by 51 · see citing works
An introduction to psychedelic neuroscience
Calvey, T., & Howells, F. M. (2018) · Progress in brain research · doi:10.1016/bs.pbr.2018.09.013 · Cited by 49 · see citing works
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. A., Lifschytz, T., Heresco-Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 33 · see citing works
Review of otential sychedelic reatments for PTSD
Henner, R. L., Keshavan, M. S., & Hill, K. P. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120302 · Cited by 49 · see citing works
Weiss, B., Nygart, V., Pommerencke, L. M., Carhart-Harris, R. L., & Erritzoe, D. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.749788 · Cited by 47 · see citing works
Rudin, D., Liechti, M. E., & Luethi, D. (2021) · Experimental Neurology · doi:10.1016/j.expneurol.2021.113778 · Cited by 48 · see citing works
Psychedelic Mushrooms in the USA: Knowledge, Patterns of Use, and Association With Health Outcomes
Matzopoulos, R., Morlock, R., Morlock, A., Lerer, B., & Lerer, L. B. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.780696 · Cited by 46 · see citing works
Adolescent Psychedelic Use and Psychotic or Manic Symptoms
Simonsson, O., Mosing, M., Osika, W., Ullén, F., Larsson, H., Lu, Y., & Wesseldijk, L. (2024) · JAMA psychiatry · doi:10.1001/jamapsychiatry.2024.0047 · Cited by 42 · see citing works
The role of substance use, smoking, and inflammation in risk for suicidal behavior
Chang, H. B., Munroe, S., Gray, K., Porta, G., Douaihy, A. B., Marsland, A. L., Brent, D. A., & Melhem, N. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.005 · Cited by 47 · see citing works
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Gandy, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.029 · Cited by 46 · see citing works
Counselors’ attitudes toward psychedelics and their use in therapy
Hearn, B., Brubaker, M. D., & Richardson, G. B. (2022) · Journal of Counseling & Development · doi:10.1002/jcad.12429 · Cited by 45 · see citing works
Naturalistic Psychedelic Use: A World Apart from Clinical Care
Glynos, N. G., Fields, C. W., Barron, J., Herberholz, M., Kruger, D. J., & Boehnke, K. F. (2022) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2022.2108356 · Cited by 45 · see citing works
Honk, L., Stenfors, C. U. D., Goldberg, S. B., Hendricks, P. S., Osika, W., Dourron, H. M., Lebedev, A. V., Petrović, P., & Simonsson, O. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.01.197 · Cited by 46 · see citing works
Metabolic Fate of Hallucinogenic NBOMes
Leth-Petersen, S., Gabel-Jensen, C., Gillings, N., Lehel, S., Hansen, H. D., Knudsen, G. M., & Kristensen, J. L. (2016) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00450 · Cited by 43 · see citing works
Révész, D., Oña, G., Rossi, G. N., Rocha, J. M., SANTOS, R. G. D., Hallak, J. E. C., Alcázar‐Córcoles, M. Á., & Bouso, J. C. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.687546 · Cited by 45 · see citing works
Valeriani, G., Corazza, O., Bersani, F. S., Melcore, C., Metastasio, A., Bersani, G., & Schifano, F. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2431 · Cited by 41 · see citing works
Eleftheriou, M. E., & Thomas, E. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.707057 · Cited by 39 · see citing works
“Both interventions have also successfully demonstrated reductions in clinical symptomatology in healthy individuals (65, 66).”
BackgroundOrłowski, P., Ruban, A., Szczypiński, J., Hobot, J., Bielecki, M., & Bola, M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221089034 · Cited by 41 · see citing works
Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression
Weiss, B., Ginige, I., Shannon, L., Giribaldi, B., Murphy-Beiner, A., Murphy, R., Baker-Jones, M., Martell, J., Nutt, D. J., Carhart-Harris, R. L., et al. (2023) · Psychological Medicine · doi:10.1017/s0033291723001514 · Cited by 43 · see citing works
Sessa, B., & Fischer, F. M. (2015) · Drug Science Policy and Law · doi:10.1177/2050324515578080 · Cited by 40 · see citing works
Johnstad, P. G. (2020) · Nordic Studies on Alcohol and Drugs · doi:10.1177/1455072520963787 · Cited by 40 · see citing works
Koslowski, M., Johnson, M. W., Gründer, G., & Betzler, F. (2021) · Current Addiction Reports · doi:10.1007/s40429-021-00401-8 · Cited by 40 · see citing works
- Authors
- Krebs, T. S., & Johansen, P.-Ø.
- Affiliations
- Norwegian University of Science and Technology (NO)
- Corresponding author
- Krebs, Teri S.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-08-19
- Volume
- 8
- Issue
- 8
- Pages
- e63972
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3747247
- OpenAlex
- W2014761647
- Cited by
- 347
- References
- 58
- Citations by year
- 2026: 24 · 2025: 25 · 2024: 37 · 2023: 53 · 2022: 40 · 2021: 41 · 2020: 17 · 2019: 17 · 2018: 30 · 2017: 19 · 2016: 20 · 2015: 16 · 2014: 6 · 2013: 2
- FWCI
- 16.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Norges Forskningsråd (rcn-foriss-185924)
- Substance Abuse and Mental Health Services Administration
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Keywords
- psychedelics, LSD, psilocybin, mescaline, peyote, mental health, serious psychological distress, mental illness, non-affective psychosis, lifetime drug use, risk factors for mental illness, National Survey on Drug Use and Health
- MeSH terms
- Adolescent, Adult, Mental Disorders, Data Collection, Female, Hallucinogens, Humans, Lysergic Acid Diethylamide, Male, Mental Health, Mescaline, Middle Aged, Psilocybin, Risk Factors, United States, Odds Ratio
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
